PL2861602T3 - 7-metylo-2-[4-metylo-6-[4-(trifluorometylo)-fenylo]pirymidyn-2-ylo]-1,7-diazaspiro[4.4]nonano-6-on - Google Patents

7-metylo-2-[4-metylo-6-[4-(trifluorometylo)-fenylo]pirymidyn-2-ylo]-1,7-diazaspiro[4.4]nonano-6-on

Info

Publication number
PL2861602T3
PL2861602T3 PL13725438T PL13725438T PL2861602T3 PL 2861602 T3 PL2861602 T3 PL 2861602T3 PL 13725438 T PL13725438 T PL 13725438T PL 13725438 T PL13725438 T PL 13725438T PL 2861602 T3 PL2861602 T3 PL 2861602T3
Authority
PL
Poland
Prior art keywords
methyl
diazaspiro
nonan
pyrimidin
trifluoromethyl
Prior art date
Application number
PL13725438T
Other languages
English (en)
Polish (pl)
Inventor
Gerard M P Giblin
David T Macpherson
David R Witty
Steven J Stanway
Original Assignee
Convergence Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convergence Pharmaceuticals Limited filed Critical Convergence Pharmaceuticals Limited
Publication of PL2861602T3 publication Critical patent/PL2861602T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL13725438T 2012-05-22 2013-05-22 7-metylo-2-[4-metylo-6-[4-(trifluorometylo)-fenylo]pirymidyn-2-ylo]-1,7-diazaspiro[4.4]nonano-6-on PL2861602T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261650325P 2012-05-22 2012-05-22
GB201209015A GB201209015D0 (en) 2012-05-22 2012-05-22 Novel compounds
US201361773710P 2013-03-06 2013-03-06
EP13725438.9A EP2861602B1 (en) 2012-05-22 2013-05-22 7-Methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one

Publications (1)

Publication Number Publication Date
PL2861602T3 true PL2861602T3 (pl) 2017-05-31

Family

ID=46546493

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13725438T PL2861602T3 (pl) 2012-05-22 2013-05-22 7-metylo-2-[4-metylo-6-[4-(trifluorometylo)-fenylo]pirymidyn-2-ylo]-1,7-diazaspiro[4.4]nonano-6-on
PL16177700T PL3106464T3 (pl) 2012-05-22 2013-05-22 Nowatorskie związki

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16177700T PL3106464T3 (pl) 2012-05-22 2013-05-22 Nowatorskie związki

Country Status (27)

Country Link
US (7) US9376445B2 (show.php)
EP (3) EP2861602B1 (show.php)
JP (3) JP6169687B2 (show.php)
KR (2) KR102161101B1 (show.php)
CN (2) CN107344942B (show.php)
AU (3) AU2013265001B2 (show.php)
BR (1) BR112014029280B1 (show.php)
CA (1) CA2873956C (show.php)
CY (2) CY1118274T1 (show.php)
DK (2) DK3106464T3 (show.php)
EA (1) EA025579B1 (show.php)
ES (3) ES2602193T3 (show.php)
GB (1) GB201209015D0 (show.php)
HR (2) HRP20161349T1 (show.php)
HU (2) HUE031664T2 (show.php)
IL (4) IL235805A (show.php)
IN (1) IN2014MN02393A (show.php)
LT (2) LT3106464T (show.php)
MX (1) MX355303B (show.php)
PL (2) PL2861602T3 (show.php)
PT (2) PT3106464T (show.php)
RS (2) RS55415B1 (show.php)
SG (2) SG11201407755UA (show.php)
SI (2) SI2861602T1 (show.php)
SM (2) SMT202000210T1 (show.php)
WO (2) WO2013175205A1 (show.php)
ZA (1) ZA201408253B (show.php)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
BR112020005992A2 (pt) * 2017-09-28 2020-09-29 Biogen Inc novos sais
SG11202002707VA (en) * 2017-10-10 2020-04-29 Biogen Inc Process for preparing spiro derivatives
WO2022133097A1 (en) * 2020-12-17 2022-06-23 Biogen Ma Inc. Synthesis of compounds that modulate use-dependent voltage-gated sodium channels

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2355157T3 (es) * 2002-07-05 2011-03-23 Targacept, Inc. Compuestos diazaspirocíclico n-arilo y métodos de preparación y uso de las mismas.
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
DE602006015215D1 (de) 2005-10-10 2010-08-12 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
US8143306B2 (en) 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
GB0520578D0 (en) * 2005-10-10 2005-11-16 Glaxo Group Ltd Novel compounds
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
WO2007047474A2 (en) * 2005-10-12 2007-04-26 Vertex Pharmaceuticals Incorporated Biphenyl derivatives as modulators of voltage gated ion channels
WO2007084314A2 (en) * 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US20110294842A9 (en) 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
CN101522685A (zh) * 2006-10-12 2009-09-02 泽农医药公司 三环螺-吲哚酮衍生物及其作为治疗剂的用途
EP2117538A1 (en) * 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
ES2536694T3 (es) 2009-09-14 2015-05-27 Convergence Pharmaceuticals Limited Procedimiento para preparar derivados de alfa-carboxamida
GB201122113D0 (en) * 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
KR20140139000A (ko) * 2012-03-21 2014-12-04 인터디지탈 패튼 홀딩스, 인크 무선 네트워크에서 다른 이동국에 의한 이동국 세션의 스폰서링
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
GB201209670D0 (en) 2012-05-31 2012-07-18 Convergence Pharmaceuticals Novel compounds

Also Published As

Publication number Publication date
EP2861594A1 (en) 2015-04-22
EP2861602B1 (en) 2016-08-10
MX355303B (es) 2018-04-12
JP2015517561A (ja) 2015-06-22
EP2861602A1 (en) 2015-04-22
LT3106464T (lt) 2020-04-10
AU2017201421A1 (en) 2017-03-23
DK2861602T3 (en) 2016-11-28
IN2014MN02393A (show.php) 2015-08-21
US20200289508A1 (en) 2020-09-17
DK3106464T3 (da) 2020-03-23
US20160184306A1 (en) 2016-06-30
US20160263115A1 (en) 2016-09-15
HRP20161349T1 (hr) 2017-01-27
EP3106464B1 (en) 2020-01-08
CY1123044T1 (el) 2021-10-29
WO2013175206A1 (en) 2013-11-28
SMT201600421B (it) 2017-01-10
US10010551B2 (en) 2018-07-03
WO2013175205A1 (en) 2013-11-28
GB201209015D0 (en) 2012-07-04
IL252033A0 (en) 2017-06-29
IL235805A0 (en) 2015-02-01
CA2873956C (en) 2021-03-23
BR112014029280B1 (pt) 2022-10-04
HRP20200580T1 (hr) 2020-10-02
US9376445B2 (en) 2016-06-28
PL3106464T3 (pl) 2020-11-16
AU2013265001A1 (en) 2014-12-18
JP6378404B2 (ja) 2018-08-22
US20170304303A1 (en) 2017-10-26
US9309254B2 (en) 2016-04-12
ZA201408253B (en) 2015-12-23
US10485801B2 (en) 2019-11-26
JP2017206534A (ja) 2017-11-24
HUE031664T2 (en) 2017-07-28
EA025579B1 (ru) 2017-01-30
EP3106464A1 (en) 2016-12-21
SI2861602T1 (sl) 2017-03-31
US20150166551A1 (en) 2015-06-18
AU2017201421B2 (en) 2017-12-07
KR102161101B1 (ko) 2020-10-20
SI3106464T1 (sl) 2020-12-31
IL271330B (en) 2021-02-28
CY1118274T1 (el) 2017-06-28
EP2861594B1 (en) 2016-08-24
SMT202000210T1 (it) 2020-05-08
LT2861602T (lt) 2016-11-10
IL235805A (en) 2017-05-29
KR20200113027A (ko) 2020-10-05
EA201492169A1 (ru) 2015-04-30
CN104640867A (zh) 2015-05-20
SG11201407755UA (en) 2014-12-30
ES2602308T3 (es) 2017-02-20
SG10201703527WA (en) 2017-06-29
PT2861602T (pt) 2016-11-14
HUE049445T2 (hu) 2020-09-28
CN107344942A (zh) 2017-11-14
MX2014014274A (es) 2015-06-17
CA2873956A1 (en) 2013-11-28
RS60368B1 (sr) 2020-07-31
AU2013265001B2 (en) 2016-12-01
PT3106464T (pt) 2020-04-03
JP2015517562A (ja) 2015-06-22
JP6169687B2 (ja) 2017-07-26
CN107344942B (zh) 2020-09-25
IL252033B (en) 2019-12-31
BR112014029280A2 (pt) 2017-06-27
RS55415B1 (sr) 2017-04-28
IL280595A (en) 2021-03-25
US9737536B2 (en) 2017-08-22
ES2782088T3 (es) 2020-09-10
AU2018201653B2 (en) 2019-05-02
KR20150023401A (ko) 2015-03-05
US20180360833A1 (en) 2018-12-20
AU2018201653A1 (en) 2018-03-29
IL271330A (en) 2020-01-30
CN104640867B (zh) 2017-07-21
HK1209423A1 (en) 2016-04-01
US20150119404A1 (en) 2015-04-30
ES2602193T3 (es) 2017-02-20

Similar Documents

Publication Publication Date Title
Sleeman et al. SnapShot: The epithelial-mesenchymal transition
AP2012006192A0 (en) PyrroloÄ2,3-DÜ pyrimidine compounds.
GB201204183D0 (en) .
AP2012006242A0 (en) Anticoagulant antidotes.
PT2861602T (pt) 7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-ona
Mount et al. My Ideal Bookshelf
EP2573067A4 (en) AROMATIC BUTANE-2-OL COMPOUNDS AND MANUFACTURING METHOD AND USES THEREOF
傅良刚 et al. 粤西罗定盆地周边成矿地质环境与找矿研究
李惠 et al. 构造叠加晕新方法在小秦岭金矿带深部盲矿预测的应用
Grewal When Nice Guys Finish First
刘涛 et al. 山东胡八庄金矿围岩破碎矿体采矿方法
李威 et al. 矿山技术经济指标动态优化研究
李石桥 et al. 甘肃阳山金矿床充水因素分析
田宏伟 et al. 祁雨沟隐爆角砾岩型金矿床资源评价
López-Ruiz Phoenicians
Rodriguez Your eyes, your self
张志臣 et al. 山东莱西山后—北泊金矿区岩石变形特征及其与金矿化关系
谢覃江 et al. 云南马鹿塘金矿床地质特征及成因探讨
France et al. Openstreetmap
Bargiel Intermezzo für Orchester, op. 46. Partitur.
王宝胜 et al. 三山岛金矿新立分矿选矿厂磨矿分级系统改造与应用
Marco Aguilar Six Houses, Paired 2-2
朱松亚 Photo
邢洪波 et al. 吉林省南岔含砷金精矿细菌氧化—氰化提金试验研究
邱福胜 常闭型斜井防跑车装置在焦家金矿的应用